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ABSTRACT Information on motivations for research partic-
ipation, may enable professionals to better tailor the process of
recruitment and informed consent to the perspective of parents
and children. Therefore, this systematic review assesses moti-
vating and discouraging factors for children and their parents
to decide to participate in clinical drug research. Studies were
identified from searches in 6 databases. Two independent re-
viewers screened and selected relevant articles. Results were
aggregated and presented by use of qualitative metasummary.
38 studies fulfilled the selection criteria and were of sufficient
quality for inclusion in the qualitative metasummary. Most
mentioned motivating factors for parents were: health benefit
for child, altruism, trust in research, and relation to researcher.
Most mentioned motivating factors for children were: person-
al health benefit, altruism and increasing comfort. Fear of
risks, distrust in research, logistical aspects and disruption of
daily life were mentioned most by parents as discouraging
factors. Burden and disruption of daily life, feeling like a
Bguinea pig^ and fear of risks were most mentioned as dis-
couraging factors by children.
Conclusion: Paying attention to these motivating and dis-
couraging factors of children and their parents during the re-
cruitment and informed consent process in drug research in-
creases the moral and instrumental value of informed consent.
What is known:
• This systematic review pools the existing empirical literature on
motivations of minors and their parents to consent or dissent to
participation in clinical drug research.
• The most mentioned motivating and discouraging factors for children
and their parents to consent to participation in clinical drug research
are identified aggregated and presented by use of qualitative
metasummary.
What is new:
• This information can be used to adapt the research protocol,
recruitment, and informed consent/assent process to the needs of
children and their parents.
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INTRODUCTION
Clinical drug research with children balances between the ad-
vancement of knowledge – and consequently possible im-
provement in clinical care – and the protection of a vulnerable
population. On the one hand children are relatively incapable
of protecting their own interest and therefore need to be
protected from harm and exploitation in research.[14] On the
other hand, clinical drug research is essential to generate suf-
ficient evidence for improvements in pediatric care and drug
dosing. Current estimates of off-label or unlicensed use of
drugs range between 10 % and 60 % in the pediatric
population.[24] Precisely because clinical drug research with
children is a precarious enterprise, special attention needs to
be given to the informed consent process.
Informed consent is one of the ethical cornerstones of hu-
man research. It represents the ethical principle of respect for
persons: persons are treated as autonomous agents and per-
sons with diminished autonomy are protected.[46] In the case
of researchwith children, this means that their parents (or legal
guardians) have to consent for them. This does not mean that
children should be excluded from or ignored in the informed
consent process. The United Nations Convention on the
Rights of the Child states that children who are capable of
forming their views have a right to express those views in
any proceedings affecting the child directly.[48] Since they
are the ones undergoing the research burden and risk, con-
structions of co-consent and assent are introduced in ethical
and legal legislation to do justice to the opinion of children [1,
49, 56].
The process of informed consent and assent in clinical re-
search with children might be clear in theory, in practice it is
not. The question remains how to design this process of infor-
mation and consent/assent as to include the perspective of
children and their parents. Their perspective is vital, since they
have the key role in decision-making on research participa-
tion. One way of taking their perspective into account is to
look at the motivations children and their parents have to
endorse or decline participation in pediatric clinical research.
When professionals know to which aspects of research chil-
dren and their parents attach importance, they know what
information is relevant for their decision. And this knowledge
may enable professionals involved in research to better tailor
the process of recruitment and informed consent/assent to the
perspective and needs of parents (or legal guardians) and
children.
To our knowledge no comprehensive systematic review
exists on these motivating and discouraging factors for
children and their parents to decide to participate in clinical
drug research. Two narrative reviews exist on why parents
enroll their child in research.[16, 20] Both reviews show per-
sonal benefit and altruism as most important motivations of
parents to enroll their child in research. However, these narra-
tive reviews are not comprehensive nor systematically han-
dled. Also, these reviews do not consider children’s motiva-
tions and are not focused on pharmacological research.
Therefore, we aimed to pool the existing empirical litera-
ture on motivations of children and their parents to consent or
dissent to participation in clinical drug research. This system-
atic review attempts to answer the following research ques-
tion: What are motivating and discouraging factors for chil-
dren and their parents to decide to participate in clinical drug
research?
METHODS
This systematic review is reported in accordance with the
Preferred Reporting Items for Systematic Review and Meta-
analyses (PRISMA) statement [32]. The extra supplemental
material provides the PRISMA checklist for this manuscript
(online resource 1).
Data sources and search strategy
We searched for peer-reviewed English-language articles
using Embase, Medline, Web of Science, Pubmed,
PsycINFO and the Cumulative Index to Nursing and Allied
Health Literature (CINAHL) for empirical studies investigat-
ing the motivations (motivating and discouraging factors) of
children and their parents to consent or dissent to participation
in clinical drug trials. The search strategy was developed in
collaboration with an information specialist of the Medical
Library.
The search strategy was based on 3 concepts: 1) motivation
for participation; 2) clinical drug research; 3) children and
parents. The search strategy in Embase was as follows: (’re-
fusal to participate’/de OR ’patient participation’/de OR ’pa-
rental consent’/de OR (((refus* OR decision* OR decid* OR
allow* OR reason* ORmotivat* ORwilling* OR assent* OR
consen* OR dissent* OR attitude* OR view* OR perspec-
tive* OR choos* OR choice*) NEAR/6 (participat* OR
nonparticipat* OR enrol*))):ab,ti OR ((conflict/de OR ’moti-
vation’/de OR drive/de OR ’informed consent’/de) AND
(participat* OR nonparticipat* OR enrol*):ab,ti)) AND (’clin-
ical trial (topic)’/exp OR ’pharmacological science’/exp OR
’clinical research’/de OR ((RCT* OR trial* OR scien* OR
research*) NEAR/11 (participat* OR enrol*)):ab,ti OR ((’sci-
ence in general’/de OR research/de OR ’medical research’/de
OR ’human experiment’/de) AND (pharmacology/exp OR
’drug therapy’/exp OR (drug* OR pharmaco* OR
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42 studies were included for systematic review  
Total of  7760  records in selection 
Embase:   2460   records 
Medline:  1930   records 
Web-of-Science:  1306   records 
PubMed:   233   records 
PsycINFO:  1295   records 
CINAHL:   536  records 
4950  records after duplicates removed
Embase:   2392  records  
Medline:  620   records  
Web-of-Science:  571   records  
PubMed:   323   records 
PsycINFO:  915   records 
CINAHL:   129   records 
4842  articles excluded based on review of title and/or abstract  
Irrelevant:    4762   records 
No clinical drug trial:    53   records 
Vaccination trial:    27   records 
2810  duplicates removed 
26  records were excluded for eligibility assessment 
Article in French:    3  records 
Conference abstract:   20   records 
No full-text available:   3   records 
82  full-text articles were assessed for eligibility  
40  articles were excluded for systematic review 
Irrelevant:    17  articles 
No clinical drug trial:   17  articles 
Vaccination trial:   1  article 
Article with already published  data: 1  article 
No empirical data:    2  articles 
Narrative review:   2  articles 
4  articles were excluded from synthesis due to high risk of bias 
or low level of evidence 
38  studies included in qualitative metasummary 
of motivational and discouraging factors 
Fig. 1 PRISMA flow diagram of study identification, screening, selection and inclusion
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medication* OR psychopharmacolog*):ab,ti))) AND (child/
exp OR newborn/exp OR adolescent/exp OR adolescence/
exp OR ’child behavior’/de OR ’child parent relation’/de
OR (adolescen* OR infan* OR newborn* OR (new NEXT/
1 born*) OR baby OR babies OR neonat* OR child* OR kid
OR kids OR toddler* OR teen* OR boy* OR girl* ORminors
OR underag* OR (under NEXT/1 ag*) OR juvenil* OR
youth* OR kindergar* OR puber* OR pubescen* OR
prepubescen* OR prepubert* OR pediatric* OR paediatric*
OR school* OR preschool* OR highschool*):ab,ti). Searches
in the other databases were based on the Embase search terms.
The extra supplemental material provides the exact search
strategies in each database (online resource 2). We performed
the initial search on March 20th 2013 and updated it on
August 22th 2014.
Inclusion and exclusion criteria
Studies were included when they addressed empirical data of:
1) children and/or parents on; 2) motivations for dissent or
consent; 3) to participation in clinical drug research. We ex-
cluded articles with: 1) No empirical data; 2) Participation in
only other clinical research than drug research; 3)
Participation in vaccination studies (this religiously debated
subject might confound results); 4) Narrative reviews.
Study selection
After identification of records from the search strategy, dupli-
cates were removed from the retrieved records. In the screen-
ing phase, two reviewers (KT and WB) independently
screened titles and abstracts of identified records for relevance
to the research question. In case of discrepancy between the
primary reviewers, a third reviewer (SvdV) decided upon inclu-
sion for further eligibility assessment. In the eligibility phase,
two reviewers (KT and WB) independently assessed full-text
articles for eligibility. Again, in case of discrepancy between
the primary reviewers, a third reviewer (SvdV) decided upon
inclusion for systematic review. The PRISMA flow diagram
presented in Fig. 1 shows the process of study selection: iden-
tification, screening, eligibility assessment and inclusion.
Data extraction and study quality assessment
We extracted relevant data from the articles eligible for sys-
tematic review with the use of a data extraction form. A tem-
plate of this form can be found in the extra supplemental
material (online resource 3). The main outcome measures ex-
tracted were motivating factors and discouraging factors men-
tioned by children and/or their parents (or legal guardians).
Study population, in- and exclusion criteria, patient character-
istics, study design, and other outcome factors besides moti-
vating and discouraging factors were also extracted. We grad-
ed the level of evidence of individual studies according to
levels set by the Dutch Institute for Healthcare Improvement
(CBO) (as indicated in Tables 1 and 2) and critically appraised
the eligible articles to determine study quality and risk of bias
(according to the Critical Appraisal Skills Programme (CASP)
checklists) [15]. Studies with a very low level of evidence
(level BD^ for quantitative studies or level B-^for qualitative
studies) or high risk of bias (based on CASP checklists) were
excluded from data-synthesis of motivating and discouraging
factors.
Data-synthesis
We performed a qualitative metasummary to give an overview
of the motivating and discouraging factors mentioned by chil-
dren and their parents. A qualitative metasummary is a quan-
titatively oriented aggregation approach to research synthesis
of descriptive findings from both quantitative and qualitative
studies. [43] This approach of data-synthesis entails treating
research reports as indexes of the studies conducted, and the
research findings in these reports as indexes of the experiences
of the persons who participated in those studies. Therefore this
approach functions well for our research question concerning
motivations for participation, answered by qualitative and
quantitative research. First, we extracted motivations
Table 1 Level of evidence of
quantitative studies Level of
evidence a
Characteristics
A1 Systematic reviews involving at least two studies at A2 level, of which the
results of separate studies are consistent
A2 Randomized comparative clinical studies of good quality (randomized, double-blind con-
trolled trails) of sufficient size and consistency
B Randomized clinical trials of mediocre quality, of insufficient size, or other
comparative studies
C Non-comparative studies
D Expert opinion
a levels according to those set by the Dutch Institute for Healthcare Improvement (CBO)
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mentioned by children or their parents from the result sections
of the eligible studies regardless of how many participants
endorsed the reason. Second, we created draft lists of all men-
tioned motivations in all studies for motivating factors and
discouraging factors. Third, we grouped these motivations
per theme and presented them as aggregated data. These
themes of motivating and discouraging factors were not
predefined, but defined by the total of extracted data.
RESULTS
Study selection
Our initial search produced 4950 titles after removing dupli-
cates. After title and abstract screening, 108 records remained
for full-text eligibility assessment. After full-text review, 42
articles could be included for data-extraction and systematic
review [2–13, 18, 21–23, 25–28, 30, 31, 33–36, 38–42, 44,
45, 47, 50–53, 55, 57, 58]. Fig. 1 shows in a PRISMA flow
diagram the results of study identification, screening, eligibil-
ity assessment and inclusion. Extracted data from these 42
studies, including study characteristics, motivating and dis-
couraging factors, level of evidence and critical appraisal,
can be found in the evidence tables as extra supplemental
material (online resource 4).
Characteristics of included studies for systematic review
Of the 42 articles that were included for systematic re-
view, 26 were quantitative studies (including 15 written
questionnaires, 7 verbally administered questionnaires and
4 studies analyzing registries of consent/dissent) and 16
were qualitative studies (including 10 interview studies, 2
focus group studies, 1 interview and focus group study
and 3 studies with secondary analysis of interviews (of
which one is a case study)). The number of research sub-
jects involved per study ranged from 1 to 81 in the qual-
itative studies, and from 20 to 448 in the quantitative
studies. In 37 studies parents (or caregivers/or legal
guardians) were questioned about their motivations com-
pared to 16 studies in which children themselves were
questioned. The age of the children questioned ranged
between 6 and 21 years. The majority of these studies
included children up to 18 years of age. Three studies
included children up to 21 years of age [8, 31, 40]
Although, in Europe, we do not consider these respon-
dents children, these studies were included because the
majority of the respondents in these 3 studies were below
18 years of age. Two studies did not define the age of
their respondents [5, 36]). The included studies were very
diverse with regard to research population and setting
(e.g., PICU/NICU setting, patients with airway diseases,
with diabetes mellitus). Studies concerning oncology pa-
tients were most prevalent. Parents and children who
consented to research were questioned in 39 studies,
while 24 studies questioned respondents who dissented
to research participation. Some studies questioned respon-
dents about drug research in general or on a hypothetical
drug study protocol (vignettes). But the majority
questioned respondents in daily practice about participa-
tion in a specific drug study protocol. Most studies
entailed participation in drug protocols with a prospect
of direct benefit for the participant, only 5 drug protocols
were considered to have no prospect of direct benefit for
the participants. Table 3 shows an overview of study char-
acteristics. The extra supplemental material provides evi-
dence tables including these 42 studies with extracted data
(online resource 4).
Study quality and risk of bias
The evidence tables in the extra supplemental material show
level of evidence (based on classification in Tables 1 and 2)
and critical appraisal (including risk of bias) for individual
studies. Four studies were of insufficient quality and were
excluded from the qualitative metasummary due to very low
level of evidence (level ‘D^ or B-^) and high risk of bias. We
excluded one qualitative study because the credibility was
minimal (level of evidence B-^): the presented data did not
answer their research question and essential parts of the data
were not presented (population consisted of patients with di-
abetes mellitus and cancer, but data from cancer patients were
missing in the article). [8] We excluded three quantitative
studies due to high risk of bias: no separate analysis of adult
research subjects and children [5]; represented data did not
support article conclusions [3]; and inclusion of a very specific
study population (patients with Anorexia Nervosa) in which
treatment and research motivations cannot be looked at sepa-
rately [33]. After these four exclusions due to insufficient
quality 38 studies remained for data synthesis (qualitative
metasummary) of motivating and discouraging factors. [2–4,
6, 7, 9–12, 18, 21–23, 25–31, 34–36, 38–42, 44, 45, 47,
50–53, 55, 57, 58].
Table 2 Level of evidence of qualitative studies
Level of evidence a Characteristics
++ Credible meta-synthesis of qualitative studies
+ Credible study
+/- Study of which credibility is dubious
- Study of which credibility is minimal
a levels according to those set by the Dutch Institute for Healthcare
Improvement (CBO)
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Table 3 Study characteristics of 42 included studies for systematic review
Characteristic No. of
studies
Studies
Type of study Quantitative study 26 See categories below
- Written questionnaires 15 Barakat, 2013; Berg, 2010; Buscariollo, 2012; Cain, 2005; Cherill, 2010; Hoberman,
2013; Read, 2009; Sammons, 2007; Tait, 1998; Tait, 2003; Truong, 2011; Van
Stuijvenberg, 1998; Vanhelst, 2013; Wagner, 2006; Zupancic, 1997
- Verbally administered
questionnaires
7 Baren, 1999; Brody, 2005; Brody, 2012; Harth, 1999; Miller, 2013; Rothmier, 2003;
Wendler, 2012
- Secondary analysis of data 4 Menon, 2012; Norris, 2010; Peden, 2000; Wynn, 2010
Qualitative study 16 See categories below
- Interviews 10 Barrera, 2005; Broome, 2003; Cartwright, 2011; Koelch, 2009; Liaschenko, 2001;
MacNeill, 2013; Masiye, 2008; Patterson, 2014; Pletsch, 2001; Pletsch, 2001 (2);
Woodgate, 2010
- Focus groups a 3 Caldwell, 2003; Lebensburger, 2013
- Secondary analysis of data b 3 Deatrick, 2002; Hoehn, 2005; Oppenheim, 2005
Study population Only parents/caregivers 26 Baren, 1999; Buscariollo, 2012; Cartwright, 2011; Caldwell, 2003; Deatrick, 2002;
Harth, 1999; Hoehn, 2005; Lebensburger, 2013; Liaschenko, 2001; MacNeill,
2013; Masiye, 2008; Menon, 2012; Oppenheim, 2005; Pletsch, 2001 (2); Pletsch,
2001; Rothmier, 2003; Sammons, 2007; Tait, 1998; Truong, 2011; Tait, 2003; Van
Stuijvenberg, 1998; Vanhelst, 2013; Woodgate, 2010; Zupancic, 1997; Wynn,
2010; Hoberman, 2013
Only children 5 Broome, 2003; Cain, 2005; Cherill, 2010; Koelch, 2009; Miller, 2013
Both 11 Barakat, 2013; Barrera, 2005; Berg, 2010; Brody, 2005; Brody, 2012; Norris, 2010;
Patterson, 2014; Peden, 2000; Read, 2009; Wagner, 2006; Wendler, 2012
Setting Oncology 11 Barrera, 2005; Berg, 2010; Broome, 2003; Deatrick, 2002; Liaschenko, 2001; Miller,
2013; Oppenheim, 2005; Pletsch, 2001; Read, 2009; Truong, 2011; Woodgate,
2010
Diabetes mellitus 5 Broome, 2003; Buscariollo, 2012; Cain, 2005; Pletsch, 2001 (2); Pletsch, 2001
Airway diseases 7 Barakat, 2013; Brody, 2005; Brody, 2012; Harth, 1999; MacNeill, 2013; Rothmier,
2003; Sammons, 2007
Sickle cell disease 4 Barakat, 2013; Lebensburger, 2013; Patterson, 2014; Wynn, 2010
PICU / NICU 4 Cartwright, 2011; Hoehn, 2005; Menon, 2012; Zupancic, 1997
Sick and healthy children
(not specified)
4 Caldwell, 2003; Cherill, 2010; Vanhelst, 2013; Wendler, 2012
Anesthetics 3 Peden, 2000; Tait, 1998; Tait, 2003
Emergency department 2 Baren, 1999; Van Stuijvenberg, 1998;
Psychopharmacology 2 Koelch, 2009; Wagner, 2006
Other c 3 Masiye, 2008; Norris, 2010; Hoberman, 2013;
Type of drug
research
Real life drug study protocol 33 Barrera, 2005; Berg, 2010; Broome, 2003; Cain, 2005; Cartwright, 2011; Deatrick,
2002; MacNeill, 2013; Harth, 1999; Hoberman, 2013; Hoehn, 2005; Koelch, 2009;
Liaschenko, 2001; Masiye, 2008; Menon, 2012; Miller, 2013; Norris, 2010;
Oppenheim, 2005; Peden, 2000; Pletsch, 2001; Pletsch, 2001 (2); Read, 2009;
Rothmier, 2003; Sammons, 2007; Tait, 1998; Tait, 2003; Truong, 2011; Van
Stuijvenberg, 1998; Vanhelst, 2013; Wagner, 2006; Wendler, 2012; Woodgate,
2010; Wynn, 2010; Zupancic, 1997
Drug research in general 4 Sammons, 2007; Tait, 1998; Tait, 2003; Van Stuijvenberg, 1998
Hypothetical drug study
protocol
5 Baren, 1999; Brody, 2005; Brody, 2012; Lebensburger, 2013; Patterson, 2014
Prospect of direct
benefit
Only studies with prospect of
direct benefit
22 Baren, 1999; Brody, 2012; Cain, 2005; Cartwright, 2011; Harth, 1999; Hoberman,
2013; Hoehn, 2005; Koelch, 2009; MacNeill, 2013; Masiye, 2008; Norris, 2010;
Patterson, 2014; Peden, 2000; Pletsch, 2001 (2); Rothmier, 2003; Sammons, 2007;
Tait, 1998; Tait, 2003; Van Stuijvenberg, 1998; Wagner, 2006; Wynn, 2010;
Zupancic, 1997
Only studies with no prospect
of direct benefit
5 Barrera, 2005; Berg, 2010; Deatrick, 2002; Miller, 2013; Oppenheim, 2005
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Qualitative metasummary of motivating factors
Of the 38 articles eligible for qualitative metasummary 33
studies included motivating factors mentioned by parents to
endorse research participation of their child. Ten studies in-
cluded motivating factors mentioned by children themselves.
The extracted motivating factors mentioned by parents and
children in the individual studies can be found in the evidence
table in the supplemental information. Tables 4 and 5 give an
overview of the motivating factors for parents and children.
Individual health benefit, altruism (including helping others
and contributing to science), a general trust in research and the
relation to researchers are mentioned by parents in the highest
number of studies. Other common motivating factors
Table 3 (continued)
Characteristic No. of
studies
Studies
Both 7 Broome, 2003; Liaschenko, 2001; Menon, 2012; Pletsch, 2001; Truong, 2011;
Vanhelst, 2013; Wendler, 2012
Not specified 8 Barakat, 2013; Brody, 2005; Buscariollo, 2012; Caldwell, 2003; Cherill, 2010;
Lebensburger, 2013; Read, 2009; Woodgate, 2010
Consenters or non
consenters
Only non consenters 3 Peden, 2000; Norris, 2010; Menon, 2012
Only consenters 18 Broome, 2003; Cain, 2005; Cartwright, 2011; Deatrick, 2002; Liaschenko, 2001;
Masiye, 2008; Miller, 2013; Oppenheim, 2005; Pletsch, 2001; Pletsch, 2001 (2);
Rothmier, 2003; MacNeill, 2013; Truong, 2011; Van Stuijvenberg, 1998; Vanhelst,
2013; Wagner, 2006; Wendler, 2012; Woodgate, 2010;
Both 21 Barakat, 2013; Baren, 1999; Barrera, 2005; Berg, 2010; Brody, 2005; Brody, 2012;
Buscariollo, 2012; Caldwell, 2003; Cherill, 2010; Harth, 1999; Hoberman, 2013;
Hoehn, 2005; Koelch, 2009; Lebensburger, 2013; Read, 2009; Sammons, 2007;
Tait, 1998; Tait, 2003; Patterson, 2014; Wynn, 2010; Zupancic, 1997
PICU Pediatric Intensive Care Unit; NICU Neonatal Intensive Care Unit
a Study of Caldwell included also personal interviews; b Study of Oppenheim is a case study; c anorexia nervosa, malaria, vesico-ureteral reflux
Table 4 Metasummary of motivating factors mentioned by parents for participation of their child in clinical drug research
Motivating factor No. of studies
(total = 33)
Individual studies
Personal health benefit
for child a
31 Barakat, 2013; Baren, 1999; Barrera, 2005; Brody, 2005; Brody, 2012; Buscariollo, 2012; Caldwell, 2003;
Cartwright, 2011; Deatrick, 2002; Harth, 1999; Hoberman, 2013; Hoehn, 2005; Lebensburger, 2013;
Liaschenko, 2001; MacNeill, 2013; Masiye, 2008; Oppenheim, 2005; Patterson, 2014; Pletsch, 2001; Pletsch,
2001 (2); Read, 2009; Sammons, 2007; Tait, 1998; Tait, 2003; Truong, 2011; Van Stuijvenberg, 1998; Vanhelst,
2013; Wagner, 2006; Woodgate, 2010; Wynn, 2010; Zupancic, 1997
Altruism b 26 Baren, 1999; Barrera, 2005; Buscariollo, 2012; Caldwell, 2003; Cartwright, 2011; Deatrick, 2002; Harth, 1999;
Hoberman, 2013; Hoehn, 2005; Liaschenko, 2001; MacNeill, 2013; Patterson, 2014; Pletsch, 2001; Pletsch,
2001 (2); Read, 2009; Rothmier, 2003; Sammons, 2007; Tait, 1998; Tait, 2003; Truong, 2011; Van Stuijvenberg,
1998; Vanhelst, 2013; Wendler, 2012; Woodgate, 2010; Wynn, 2010; Zupancic, 1997
Trust in safety of
research
12 Barakat, 2013; Buscariollo, 2012; Cartwright, 2011; Harth, 1999; Hoberman, 2013; Hoehn, 2005;MacNeill, 2013;
Patterson, 2014; Tait, 1998; Truong, 2011; Vanhelst, 2013; Zupancic, 1997
Relation to researcher 12 Buscariollo, 2012; Caldwell, 2003; Harth, 1999; Hoberman, 2013; Masiye, 2008; Read, 2009; Sammons, 2007;
Tait, 1998; Tait, 2003; Truong, 2011; Woodgate, 2010; Van Stuijvenberg, 1998
More contact with
medical team
8 Buscariollo, 2012; Caldwell, 2003; Harth, 1999; Lebensburger, 2013; MacNeill, 2013; Masiye, 2008;Wynn, 2010;
Woodgate, 2010
Benefit for parents
themselves
5 Harth, 1999; Oppenheim, 2005; Rothmier, 2003; Wagner, 2006; Van Stuijvenberg, 1998;
Minimal burden for
child
4 Patterson, 2014; Pletsch, 2001 (2); Read, 2009; Woodgate, 2010
Financial
reimbursement
5 Brody, 2012; Buscariollo, 2012; Harth, 1999; Masiye, 2008; Wagner, 2006
Felt as only option c 4 Cartwright, 2011; Deatrick, 2002; Liaschenko, 2001; Oppenheim, 2005
Influence of family and
friends
3 Buscariollo, 2012; Harth, 1999; Read, 2009
a factor mentioned in studies with and without prospect of direct benefit; b In 3 studies specifically defined as no motivating factor; c all studies were in
oncology setting
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mentioned by parents to endorse research participation of their
child include: more contact with the medical team, benefit for
parents themselves, a sense of minimal burden for their child,
the opportunity of financial reimbursement, feelings of having
no other option, and influence of family and friends. For chil-
dren themselves the most frequently mentioned factor favor-
ing research participation include personal health benefit, al-
truism and increasing comfort by participation. Other motivat-
ing factors mentioned in multiple studies by children are the
relation to the researcher, influence of family and friends, a
financial reimbursement, increasing their knowledge about
their disease and a sense of curiosity. In one study children
alsomentioned the feeling of having no other option available.
Qualitative metasummary of discouraging factors
Of the 38 articles eligible for qualitative metasummary 24
studies included discouraging factors mentioned by parents
for research participation of their child. Six studies included
discouraging factors mentioned by children themselves. These
include motivations mentioned by respondents who dissented
to research participation, but also discouraging factors men-
tioned by respondents who did participate but considered
these factors as negatively influencing their decision. The ex-
tracted discouraging factors mentioned by parents and chil-
dren in the individual studies can be found in the evidence
table in the extra supplemental material. Tables 6 and 7 give an
overview of the discouraging factors for parents and children.
Fear of potential risks, a general distrust in research, logistical
aspects and disruption of daily life and fear of burden for their
child are mentioned by parents in the highest number of stud-
ies. Other common discouraging factors mentioned in multi-
ple studies by parents for research participation of their child
include: decision considered to be too stressful, a fear of ran-
domization, no prospect of direct benefit for their child, finan-
cial constraints and a discomfort with being a proxy.
Discouraging factors incidentally mentioned by parents are
for example a discord between guardians, religious constraints
or privacy issues. For children themselves the most frequently
mentioned factors discouraging research participation include
fear of burden for themselves and disruption of their daily life,
feeling like a Bguinea pig^ and a fear of risks. Other discour-
aging factors incidentally mentioned by children are the pros-
pect of no direct benefit, no understanding of the study, pref-
erence for one arm and the decision considered to be too
stressful.
DISCUSSION
This systematic review shows that the most frequently men-
tioned motivating factors for parents to endorse their child’s
participation in clinical drug research are: health benefit for
their child, altruism, a trust in research, and their relation to the
researcher. Most frequently mentioned motivating factors for
children to participate are: personal health benefit, altruism
and increasing comfort. Fear of risks, a distrust in research,
logistical aspects and disruption of daily life are mentioned
most frequently as discouraging factors to endorse participa-
tion of their child by parents. Burden and disruption of daily
life, feeling like a Bguinea pig^ and fear of risks were most
frequently mentioned as discouraging factors by children.
One of the most important ethical criteria on which a re-
search ethics board (REB) should evaluate a research proto-
col, is whether the objective outweighs the risk and burden to
the research subjects: called a consideration of proportionality.
Table 5 Metasummary of
motivating factors mentioned by
children for participation in
clinical drug research
Motivating factor No. of studies
(total = 10)
Individual studies
Personal health
benefita
8 Barrera, 2005; Brody, 2005; Brody, 2012; Cain, 2005; Miller, 2013;
Patterson, 2014; Read, 2009; Wagner, 2006
Altruism 6 Cain, 2005;Miller, 2013; Patterson, 2014; Read, 2009;Wagner, 2006;
Wendler, 2012
Increasing comfort 4 Cain, 2005; Koelch, 2009; Miller, 2013; Read, 2009
Relation to
researcher
3 Miller, 2013; Read, 2009; Wagner, 2006
Influence of family
and friends
3 Cain, 2005; Read, 2009; Wagner, 2006
Financial
reimbursement
3 Brody, 2005; Brody, 2012; Wagner, 2006
Increasing
knowledge
2 Cain, 2005; Wagner, 2006
Curiosity 2 Cain, 2005; Koelch, 2009
Felt as only option 1 Miller, 2013
a factor mentioned in studies with and without prospect of direct benefit
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In other words: an REB assesses the predictable risk
and burden to the research subjects in comparison to
the foreseeable benefit to them and to other individuals
or groups affected by the investigated condition.[56]
Our review shows that this proportionality is also con-
sidered by parents and children in their own individual
decision about research participation; personal health
benefit and altruism are the most frequently mentioned
motivating factors and risk and burden are frequently
mentioned as discouraging factors. In 7 studies the
weighing of these factors (proportionality) is even
specifically mentioned by parents.[2, 11, 27, 35, 38,
39, 45] In 2 studies children mention explicit this pro-
portionate weighing.[25, 35].
Burden of participation
The results also show that it is not only burden for the
participating child that influences the decision, but also
burden for parents themselves and the rest of their
family. Professionals involved in pediatric research need
to be aware that when a child participates in research, a
Table 6 Metasummary of
discouraging factors mentioned
by parents for participation of
their child in clinical drug
research
Discouraging factor No. of studies
(total = 24)
Individual studies
Fear of risks 14 Baren, 1999; Brody, 2005; Brody, 2012; Buscariollo, 2012;
Caldwell, 2003; Harth, 1999; Hoehn, 2005; Lebensburger, 2013;
MacNeill, 2013; Patterson, 2014; Pletsch, 2001 (2); Read, 2009;
Tait, 1998; Tait, 2003;
Distrust in research
(Bguinea pig^)
11 Baren, 1999; Caldwell, 2003; Harth, 1999; Hoehn, 2005;
Lebensburger, 2013; Menon, 2012; Peden, 2000; Read, 2009;
Sammons, 2007; Tait, 1998; Wynn, 2010
Logistics / disruption
of daily life a
11 Baren, 1999; Brody, 2005; Caldwell, 2003; Patterson, 2014; Harth,
1999; Lebensburger, 2013; Peden, 2000; Pletsch, 2001; Read,
2009; Tait, 1998; Wynn, 2010
Burden for child 9 Barrera, 2005; Brody, 2005; Buscariollo, 2012; Menon, 2012;
Oppenheim, 2005; Peden, 2000; Pletsch, 2001 (2); Read, 2009;
Woodgate, 2010
Decision too stressful 7 Hoberman, 2013; Lebensburger, 2013; Menon, 2012; Pletsch, 2001;
Read, 2009; Sammons, 2007; Tait, 1998
Fear of
randomization
6 Caldwell, 2003; Lebensburger, 2013; MacNeill, 2013; Sammons,
2007; Tait, 1998; Wynn, 2010
No direct benefit for
child b
5 Baren, 1999; Barrera, 2005; MacNeill, 2013; Read, 2009; Wynn,
2010
Financial constraints 5 Baren, 1999; Buscariollo, 2012; Harth, 1999; Tait, 1998; Wynn,
2010
Discomfort with
proxy consent
2 Buscariollo, 2012; Caldwell, 2003
a for child and rest of family; b of which 3 are defined as studies with no prospect of direct benefit
Table 7 Metasummary of
discouraging factors mentioned
by children for participation in
clinical drug research
Discouraging factor No. of studies
(total = 6)
Individual studies
Burden / disruption of daily
life
4 Brody, 2005; Koelch, 2009; Read, 2009; Patterson,
2014
Feeling like a Bguinea pig^ 3 Koelch, 2009; Peden, 2000; Read, 2009
Fear of risks 3 Brody, 2005; Brody, 2012; Patterson, 2014
Decision too stressful 1 Read, 2009
No understanding 1 Read, 2009
No direct benefit 1 Read, 2009
Preference for one arm 1 Peden, 2000
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lot of the burden falls on the shoulders of parents: e.g.,
they need to be present at the hospital, they are often
the ones filling in the diaries. This burden may nega-
tively affect the decision of parents to let their child
participate in research. That is also true for logistical
aspects and disruption of the lives of the whole family.
Parents are the ones absent from work and they need to
make sure that other family members are looked after
when their child participates in research. Parents
mention for example Bthe inconveniences of trial
participation^ [11] or Btoo many visits^ [57] as reasons
for dissent.
General trust and mistrust in research
Issues of general trust in research or general mistrust (often
explained with wordings as Bguinea pig^) influence the deci-
sion of parents and children greatly. These issues of trust and
mistrust might indicate that their decision is not a weighing of
factors but an a priori decision. This idea of an a priori deci-
sion was also suggested a few years ago by W. Pinxten in his
thesis. [37] The general trust of children and their parents in
research needs to be protected by careful evaluation of study
protocols by an REB beforehand. A proper evaluation system
beforehand ensures that the studies offered to parents and
children are of such quality that their trust in research is
well-founded.
Personal health benefit
Personal health benefit is one of the most important motiva-
tors for parents and children themselves to participate in clin-
ical drug research. This is of course not problematic when the
study has therapeutic objectives, but is problematic when no
prospect of direct benefit exists.
In all 3 studies with no prospect of direct benefit (all on-
cology phase 1 studies) where parents were questioned, pos-
sible health benefit for their child was a motivating factor. [4,
18, 34] In the study of Deatrick et al. most parents saw their
child’s participation in the trial as Ba means of providing treat-
ment to prolong life, though an uncertain treatment^. [18] In
the study of Barrera et al. families main motivator for enroll-
ing in phase 1 trials was Bhope for a cure or prolongation of
the child’s life and their belief that participating would ensure
continuity of care^. [4] Since the objective of these phase 1
studies is safety assessment and not effectiveness, and because
of the fading boundary between research and care, therapeutic
misconception is a clear danger in these studies.[17] Adequate
information on the rationale of the study is therefore essential.
Professionals involved in clinical research need to be aware
that the line between hope and reality is thin. As illustrated by
an interviewed mother from the study from Oppenheim: B…
the study was proposed as an alternative, and we accepted it
to avoid the operation and to gain more time, even a week, but
not really believing that it could cure F .^ [34].
Children are also vulnerable to therapeutic misconception,
as shown in two studies with no prospect of direct benefit in
which children themselves mention therapeutic benefit as an
important motivating factor. [4, 31].
Altruism
Helping others or contributing to science is an important mo-
tivation for parents to endorse participation in clinical drug
research. However, 3 studies concluded that altruism was ex-
plicitly not a factor in the decision of parents. [2, 34, 52]
Altruistic motivations might be overestimated in this review.
These could be socially desirable answers. Remarkable is the
finding of Truong et al., that parents with a child in a phase 3
study mention altruistic motivations more often than parents
with a child in phase 1 studies. [47].
Helping others and contributing to science were also men-
tioned frequently by children as a motivation for participation
in research. For example, more than 80 % of the questioned
children in the study of Wendler et al. indicated that finding
better treatments for others was important to their decision to
enroll. [53] Two studies that showed altruistic motivations in
children questioned children starting at an age of 6 years old.
This might indicate that children can be altruistic at a much
younger age than currently suggested.[54] Unfortunately, the
studies addressing altruism had very wide age ranges (6-18
years) and no stratified analyses for age groups. It would be
interesting to look deeper into the role of altruistic motivations
of children in pediatric research.
Relation to researcher
Parents and children mention their relation to the researcher
quite often as a factor influencing their decision to participate.
This should not be a problem if they ask him/her for advice or
feel safe with him/her. But it is problematic when parents and
children use words as BI felt pressure^[40] or even BThey told
me to^[52]. This means that parents and children may feel less
free when asked to participate. The effect of this relationship
on their decision needs to be considered even more carefully
when the roles of researcher and treating physician converge
in one, which is often the case in pediatrics. [19].
More contact with medical team
Parents mentioned quite often more contact with the medical
team as a favoring factor for endorsing research participation .
For example, in the study by Masiye et al, some participants
felt that if they would refuse to participate in the study, their
child might not receive attention from the healthcare workers
whenever they would visit the hospital again. [29] And some
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parents in Caldwell’s stated that their child would be better
monitored when he/she would be in the trial.[11] This sug-
gests that parents think their child is better looked after or
treated when in research. Parents need to be aware that (non)
participation in research does not affect their regular treat-
ment. In our opinion, a patient should not be dependent on
research to get the attention he/she wishes for in a treatment
setting.
Felt as only option
Striking is the observation that parents sometimes endorse
participation because it feels for them as if they do not have
an option. [12, 18, 27, 31, 40] This can be a problematic
factor, when there are other options available of which parents
are not sufficiently aware of. But in certain hospital settings
(for example oncology setting) participation in research is
indeed the only option parents and children have opposed to
palliative care. Furthermore, some children and parents can
only accept the child’s upcoming death when they have tried
all available options. One parent illustrated this clearly in a
study by Deatrick et. al.: BThere wasn’t really a choice in my
mind because if I choose to not do anything then I would have
been choosing to let her go and I’m not ready for that.^[18].
No direct benefit for child
Surprisingly, this review shows parents can refuse participa-
tion because they do not expect benefit for their child. It is
striking that this is mentioned in 3 randomized phase 3 studies
(where a prospect of benefit exists). [3, 28, 57] A possible
explanation could be that parents have a preference for the
experimental intervention arm (compared to standard or pla-
cebo arm) and are suspicious of the randomization since it
does not guarantee them access to the experimental interven-
tion arm. This is illustrated in the study by Baren et. al in
which parents mention fear of receiving less than optimal
treatment in the study as a discouraging factor for participation
[3].
Limitations and strengths of this review
This systematic review gives a comprehensive overview of
motivating and discouraging factors for children and their par-
ents to consent to clinical drug research. Since we aimed to
give an overview of all the available empirical literature on
this topic, there is a large variety in drug trials, settings and
populations of the studies. This heterogeneity in studies might
complicate the interpretation of the pooled data, but we feel it
is essential to pool these heterogeneous results, since it reflects
the diverse practice of pediatric drug trials.
Because of challenges in the search strings, we limited our
research question to participation in pharmacological
research. Therefore it is uncertain whether we can extrapolate
these results to other medical research (including observation-
al research and other interventional research).
We reported in the qualitative metasummary the number of
studies citing a specific factor. The number of articles
reporting a specific factor may not represent the importance
of this factor to the research participants. Besides that, given
the wide range in the number of research participants per
study, an increasing number of studies citing a factor, does
not necessarily reflect more parents or children mentioning
this factor. However, qualitative metasummary is still the best
way to pool this kind of data from qualitative and quantitative
empirical studies. To get more insight in the motivations of
parents and children qualitative research is of essential value
and a large portion of the data in this review comes from
qualitative data. Therefore, this way of pooling the data does
justice to the diversity in qualitative and quantitative research
available for answering our research question. By including
qualitative and quantitative research the strengths of both
types of research are combined; in depth results and possibil-
ity of unanticipated motivations from qualitative research, and
large sample sizes and standardization from quantitative
research.
Conclusion
It is essential that professionals during the recruitment and
informed consent/assent process pay attention to the motivat-
ing and discouraging factors children and their parents have
for participation in clinical drug research When professionals
know more about the motivations of parents and children to
endorse or decline participation in clinical drug research, pro-
fessionals know which aspects of research parents and chil-
dren attach importance to and what information is of relevance
for their decision. This information can then be used by pro-
fessionals in the informed consent materials and conversa-
tions. When children and their parents are being informed
about the aspects of research to which they attach importance,
they may reach a decision more consistent with their own
values. Therefore, the attention to these motivating and dis-
couraging factors makes the informed consent/assent of par-
ents and children more informed, which thus increases the
moral value of informed consent/assent.
Besides leading to an increase in the moral value of in-
formed consent, paying attention to the motivations of chil-
dren and their parents for participation in clinical drug re-
search can also be of instrumental value. By adapting the
study protocol, the recruitment and the informed consent pro-
cess to the needs and wishes of children and their parents,
participation rates will probably increase (and dropout rates
can decrease). For example, by diminishing logistical barriers
(which this review shows, are mentioned often by parents as
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negatively influencing their decision) at the setup of the study,
parents and children will probably be more inclined to partic-
ipate. Therefore, adapting the research protocol, recruitment
and informed consent process to the needs of children and
their parents may lead to more informed consents.
This systematic review gives a comprehensive overview of
the available empirical data on motivating and discouraging
factors for parents and children to consent/assent to clinical
drug research. But it also shows us that specific populations
are underrepresented in this field of research. Further research
is needed in diverse populations and research fields (for ex-
ample healthy children, children with chronic disease such as
cystic fibrosis, and critically ill children). This future research
should specifically focus on the factors that shape the decision
of children themselves, since research with children on this
topic is scarce. Although children cannot consent by them-
selves, they can assent and we shouldn’t forget to listen to
them. They are the ones bearing the burden and risk during
participation in clinical drug research, and possible beneficia-
ries of the research.
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